Please provide your email address to receive an email when new articles are posted on . The accompanying cover story summarizes some pioneering activities in collagen cross-linking for keratoconus. In ...

Please provide your email address to receive an email when new articles are posted on . Corneal cross-linking is the best noninvasive step to protect patients with intellectual disability and ...

SHERBORN, Mass.--(BUSINESS WIRE)--CXL Ophthalmics, Inc., a clinical-stage company developing a minimally-invasive treatment for keratoconus, today published results of the EpiSmart cross-linking Phase ...

On Monday, Glaukos Corporation (NYSE:GKOS) received the “Day 74” notification from the U.S. Food and Drug Administration (FDA) acknowledging the previously submitted New Drug Application (NDA) for ...

Glaukos (GKOS) announced the submission of its New Drug Application NDA to the U.S. Food and Drug Administration FDA or Epioxa or Epi-on, its next-generation corneal cross-linking iLink therapy for ...

To evaluate the safety and efficacy of repeated corneal collagen crosslinking assisted by transepithelial double-cycle iontophoresis (DI-CXL) in the management of keratoconus progression after primary ...

We wanted to share and raise these philosophical questions—does the ophthalmologist have to witness disease progression before intervention? Who determines progression—the patient or the doctor? [3] ...

(MASS APPEAL) – If you’ve been diagnosed with Keratoconus then Corneal Cross Linking might get you back to better eyesight. Mass Appeal’s Patrick Berry joined Dr. John P. Frangie, MD to learn more.

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal ...

A patient in their early 40s presented with a bilateral gradual painless decrease in vision. Best-corrected visual acuity (BCVA) was 20/40p OD and 20/20 OS. Tomography using Pentacam (OCULUS) ...